Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Boehringer Ingelheim7,391 enrolled

Overview

The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).

Study Type

OBSERVATIONAL

Enrollment

7,391

Conditions

Prostatic Hyperplasia

Interventions

TamsulosinDRUG

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Indication for the treatment with ALNA according to its summary of product characteristics (SPC) Exclusion Criteria: * Patients fulfilling one of the general or specific contraindications listed in the ALNA SPC, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency cannot be included in the study

Outcomes

Primary Outcomes

Collection of information on concomitant diseases

Time frame: day 1

Collection of information on concomitant treatment

Time frame: day 1

Secondary Outcomes

Number of patients with adverse drug reactions

Time frame: up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.